Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125231121 | 12523112 | 1 | I | 20150809 | 20160131 | 20160701 | 20160701 | EXP | PR-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-052215 | BRISTOL MYERS SQUIBB | 0.00 | DY | M | Y | 1.90000 | KG | 20160701 | OT | PR | PR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125231121 | 12523112 | 1 | PS | STAVUDINE. | STAVUDINE | 1 | Transplacental | 1 DF, QD | U | 20412 | 1 | DF | QD | ||||||
| 125231121 | 12523112 | 2 | SS | LAMIVUDINE. | LAMIVUDINE | 1 | Transplacental | 1 DF, QD | U | 0 | 1 | DF | QD | ||||||
| 125231121 | 12523112 | 3 | SS | DARUNAVIR | DARUNAVIR | 1 | Transplacental | 1 DF, QD | U | 0 | 1 | DF | QD | ||||||
| 125231121 | 12523112 | 4 | SS | RITONAVIR. | RITONAVIR | 1 | Transplacental | 1 DF, QD | U | 0 | 1 | DF | QD | ||||||
| 125231121 | 12523112 | 5 | SS | EMTRICITABINE W/TENOFOVIR DISOPROXIL FUMARATE | EMTRICITABINETENOFOVIR DISOPROXIL | 1 | Transplacental | 1 DF, QD | U | 0 | 1 | DF | QD | ||||||
| 125231121 | 12523112 | 6 | SS | LAMIVUDINE W/ZIDOVUDINE | LAMIVUDINEIDOVUDINE | 1 | Transplacental | 1 DF, QD | U | 0 | 1 | DF | QD | ||||||
| 125231121 | 12523112 | 7 | SS | LOPINAVIR W/RITONAVIR | LOPINAVIRRITONAVIR | 1 | Transplacental | 1 DF, QD | U | 0 | 1 | DF | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125231121 | 12523112 | 1 | Product used for unknown indication |
| 125231121 | 12523112 | 2 | Product used for unknown indication |
| 125231121 | 12523112 | 3 | Product used for unknown indication |
| 125231121 | 12523112 | 4 | Product used for unknown indication |
| 125231121 | 12523112 | 5 | Product used for unknown indication |
| 125231121 | 12523112 | 6 | Product used for unknown indication |
| 125231121 | 12523112 | 7 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125231121 | 12523112 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125231121 | 12523112 | Foetal exposure during pregnancy | |
| 125231121 | 12523112 | Low birth weight baby |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |